Daily Archives: July 25, 2009

Lopinavir was developed by Abbott in an attempt to improve on the AIDS/HIV resistance and serum protein-binding properties of the company’s earlier protease inhibitor, ritonavir. Given alone, lopinavir has too low of abioavailability, but, like many HIV protease inhibitors its blood plasma levels can be greatly increased by using low doses of rionavir. Continue reading